Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

18F-FET (O-(2-[18F]Fluoroethyl)-L-tyrosine) PET in Differentiating Tumour Progression From Pseudoprogression in High Grade Gliomas

NCT06172595 is registered in ClinicalTrials.gov with Singapore General Hospital as lead sponsor.

NCT NCT06172595
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06172595 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
18F-FET (O-(2-[18F]Fluoroethyl)-L-tyrosine) PET in Differentiating Tumour Progression From Pseudoprogression in High Grade Gliomas
Lead sponsor
Singapore General Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
December 21, 2023
Completion date
February 28, 2026
Enrollment
22 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

glioma, malignant